Immunogenic engineered live-attenuated gram-negative pathogen vaccines having reduced endotoxicity
AssigneesUniversity of Maryland, Baltimore, The Government of The United States, as represented by the Defense Health Agency
InventorsRobert K. Ernst, Matthew Sherman, Jane M. Wilhelm, Shoshana Barnoy, Malabi Venkatesan
Life of this patent
Estimating the term…
Abstract
The present invention provides genetically modified Gram-negative microorganisms with reduced endotoxicity, wherein the Gram-negative microorganism is genetically modified to express a lipid A 1-phosphatase.
Claims20
A genetically modified Shigella microorganism with reduced endotoxicity, wherein the Shigella is genetically modified to express a lipid A 1-phosphatase.
A genetically modified Gram-negative microorganism with reduced endotoxicity, wherein the microorganism is genetically modified to express a lipid A 1-phosphatase.
Dependencies are inferred from the claim text.